Logo image of IMNM

IMMUNOME INC (IMNM) Stock Fundamental Analysis

NASDAQ:IMNM - Nasdaq - US45257U1088 - Common Stock - Currency: USD

9.52  -0.59 (-5.84%)

After market: 9.83 +0.31 (+3.26%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMNM. IMNM was compared to 572 industry peers in the Biotechnology industry. While IMNM has a great health rating, there are worries on its profitability. IMNM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

IMNM had negative earnings in the past year.
In the past year IMNM has reported a negative cash flow from operations.
IMNM had negative earnings in each of the past 5 years.
IMNM had a negative operating cash flow in each of the past 5 years.
IMNM Yearly Net Income VS EBIT VS OCF VS FCFIMNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

IMNM has a Return On Assets of -118.86%. This is in the lower half of the industry: IMNM underperforms 79.93% of its industry peers.
IMNM's Return On Equity of -142.08% is on the low side compared to the rest of the industry. IMNM is outperformed by 63.94% of its industry peers.
Industry RankSector Rank
ROA -118.86%
ROE -142.08%
ROIC N/A
ROA(3y)-90.19%
ROA(5y)-103.39%
ROE(3y)-121.9%
ROE(5y)-145.82%
ROIC(3y)N/A
ROIC(5y)N/A
IMNM Yearly ROA, ROE, ROICIMNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

IMNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNM Yearly Profit, Operating, Gross MarginsIMNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -200 -400 -600

8

2. Health

2.1 Basic Checks

IMNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMNM has more shares outstanding
Compared to 5 years ago, IMNM has more shares outstanding
IMNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMNM Yearly Shares OutstandingIMNM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
IMNM Yearly Total Debt VS Total AssetsIMNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

An Altman-Z score of 8.04 indicates that IMNM is not in any danger for bankruptcy at the moment.
IMNM has a Altman-Z score of 8.04. This is amongst the best in the industry. IMNM outperforms 85.26% of its industry peers.
There is no outstanding debt for IMNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.04
ROIC/WACCN/A
WACC9.44%
IMNM Yearly LT Debt VS Equity VS FCFIMNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 6.17 indicates that IMNM has no problem at all paying its short term obligations.
IMNM's Current ratio of 6.17 is fine compared to the rest of the industry. IMNM outperforms 62.17% of its industry peers.
A Quick Ratio of 6.17 indicates that IMNM has no problem at all paying its short term obligations.
IMNM has a better Quick ratio (6.17) than 62.52% of its industry peers.
Industry RankSector Rank
Current Ratio 6.17
Quick Ratio 6.17
IMNM Yearly Current Assets VS Current LiabilitesIMNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M

2

3. Growth

3.1 Past

The earnings per share for IMNM have decreased strongly by -234.92% in the last year.
IMNM shows a decrease in Revenue. In the last year, the revenue decreased by -0.60%.
EPS 1Y (TTM)-234.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.31%
Revenue 1Y (TTM)-0.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.49%

3.2 Future

Based on estimates for the next years, IMNM will show a decrease in Earnings Per Share. The EPS will decrease by -8.27% on average per year.
Based on estimates for the next years, IMNM will show a very strong growth in Revenue. The Revenue will grow by 78.64% on average per year.
EPS Next Y-346.4%
EPS Next 2Y-71.47%
EPS Next 3Y-44.62%
EPS Next 5Y-8.27%
Revenue Next Year-23.24%
Revenue Next 2Y-49.74%
Revenue Next 3Y13.37%
Revenue Next 5Y78.64%

3.3 Evolution

IMNM Yearly Revenue VS EstimatesIMNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IMNM Yearly EPS VS EstimatesIMNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMNM. In the last year negative earnings were reported.
Also next year IMNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNM Price Earnings VS Forward Price EarningsIMNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNM Per share dataIMNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

IMNM's earnings are expected to decrease with -44.62% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-71.47%
EPS Next 3Y-44.62%

0

5. Dividend

5.1 Amount

No dividends for IMNM!.
Industry RankSector Rank
Dividend Yield N/A

IMMUNOME INC

NASDAQ:IMNM (2/21/2025, 8:00:01 PM)

After market: 9.83 +0.31 (+3.26%)

9.52

-0.59 (-5.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners63.03%
Inst Owner Change-97.87%
Ins Owners1.68%
Ins Owner Change8.84%
Market Cap759.51M
Analysts87.69
Price Target30.6 (221.43%)
Short Float %13.39%
Short Ratio9.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.89%
Min EPS beat(2)-22.13%
Max EPS beat(2)-17.65%
EPS beat(4)0
Avg EPS beat(4)-413.67%
Min EPS beat(4)-1360.22%
Max EPS beat(4)-17.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)12.31%
Min Revenue beat(2)-9.11%
Max Revenue beat(2)33.73%
Revenue beat(4)2
Avg Revenue beat(4)10.47%
Min Revenue beat(4)-63.97%
Max Revenue beat(4)81.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)7.85%
EPS NQ rev (3m)3.9%
EPS NY rev (1m)0.97%
EPS NY rev (3m)-6.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 74.98
P/FCF N/A
P/OCF N/A
P/B 3.53
P/tB 3.53
EV/EBITDA N/A
EPS(TTM)-7.89
EYN/A
EPS(NY)-2.91
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.13
BVpS2.69
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -118.86%
ROE -142.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.19%
ROA(5y)-103.39%
ROE(3y)-121.9%
ROE(5y)-145.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4152.22%
Cap/Sales 518.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.17
Quick Ratio 6.17
Altman-Z 8.04
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)83.96%
Cap/Depr(5y)73.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-234.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.31%
EPS Next Y-346.4%
EPS Next 2Y-71.47%
EPS Next 3Y-44.62%
EPS Next 5Y-8.27%
Revenue 1Y (TTM)-0.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.49%
Revenue Next Year-23.24%
Revenue Next 2Y-49.74%
Revenue Next 3Y13.37%
Revenue Next 5Y78.64%
EBIT growth 1Y-392.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-902.42%
EBIT Next 3Y-96.14%
EBIT Next 5YN/A
FCF growth 1Y-378.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-199.07%
OCF growth 3YN/A
OCF growth 5YN/A